At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 39 enrolled
Drug / intervention
MORF-057drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Tolerability of MORF-057 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-1)
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)·interventional·Posted Mar 23, 2022·Updated Mar 11, 2026
In Brief
A Phase 2 clinical trial evaluating MORF-057 for Inflammatory Bowel Diseases and Colitis, Ulcerative. Completed, enrolled 39 participants across 17 sites in 2 countries.
Detailed Summary
This is an open-label, single arm, multicenter, Phase 2a study evaluating the efficacy, safety, and tolerability of MORF-057 in adult patients with Moderately to Severely Active Ulcerative Colitis (UC)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammatory Bowel Diseases, Colitis, Ulcerative
CountriesPoland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedMar 2022
Enrollment StartApr 2022
Primary CompletionOct 2023
Study CompletionFeb 2025
TodayJul 2026
First PostedMar 23, 2022
Enrollment StartApr 13, 2022
Primary CompletionOct 18, 2023
Study CompletionFeb 19, 2025
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 4.3 years ago
Interventions
MORF-057drug
MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.